Sign Up to like & get
recommendations!
0
Published in 2017 at "Hematological Oncology"
DOI: 10.1002/hon.2438_119
Abstract: rubicin, epirubicin, vinblastine, etoposide, paclitaxel, and topotecan. RTI‐79's PK characteristics are similar to rifabutin and exhibited no overt toxicity in mice at high doses. RTI‐79 did not exacerbate the known cardiotoxicity associated with doxorubicin as…
read more here.
Keywords:
rti;
novel preclinical;
secondary resistance;
preclinical models ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-020-01691-0
Abstract: Oncogenic RAS mutations are negative biomarkers of response to epidermal growth factor receptor (EGFR) blockade. RAS mutations are usually detected in biopsies of primary colorectal tumors. However, the genomic profiles of primary tumors and metastases…
read more here.
Keywords:
egfr;
secondary resistance;
ras mutations;
ras braf ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2020-002092
Abstract: Background Although the Society for Immunotherapy of Cancer (SITC) Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-programmed cell death protein 1 (anti-PD-1) therapy, there is lack of real-world data regarding differences in…
read more here.
Keywords:
advanced melanoma;
secondary resistance;
resistance;
anti monotherapy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "BMC Microbiology"
DOI: 10.1186/s12866-021-02136-y
Abstract: Background The issue of carbapenem resistance in E.coli is very concerning and it is speculated that cumulative effect of both primary resistance genes and secondary resistance genes that act as helper to the primary resistance…
read more here.
Keywords:
secondary resistance;
bla ndm;
resistance;
carbapenem ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1144534
Abstract: Background Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer immunotherapy, but secondary resistance (SR) and immune-related adverse events (irAEs) are significant clinical dilemmas. Although the gut microbiota is associated with ICI efficacy and…
read more here.
Keywords:
immune checkpoint;
gut microbiota;
secondary resistance;
resistance ... See more keywords